BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $535,030 | -16.6% | 7,860 | 0.0% | 0.02% | -12.5% |
| Q2 2023 | $641,612 | +10.0% | 7,860 | 0.0% | 0.02% | +4.3% |
| Q1 2023 | $583,133 | -54.7% | 7,860 | -49.5% | 0.02% | -55.8% |
| Q4 2022 | $1,288,456 | +15.6% | 15,560 | +295.9% | 0.05% | +4.0% |
| Q3 2022 | $1,115,000 | -18.1% | 3,930 | 0.0% | 0.05% | -15.3% |
| Q2 2022 | $1,361,000 | -20.0% | 3,930 | 0.0% | 0.06% | -3.3% |
| Q1 2022 | $1,702,000 | -16.2% | 3,930 | 0.0% | 0.06% | -10.3% |
| Q4 2021 | $2,032,000 | +6.6% | 3,930 | -0.2% | 0.07% | -2.9% |
| Q3 2021 | $1,906,000 | -71.1% | 3,936 | -73.1% | 0.07% | -70.3% |
| Q2 2021 | $6,592,000 | +22.4% | 14,643 | -1.1% | 0.24% | +15.1% |
| Q1 2021 | $5,387,000 | +14.7% | 14,802 | +0.0% | 0.20% | -4.7% |
| Q4 2020 | $4,698,000 | +26.1% | 14,796 | -1.6% | 0.22% | +27.2% |
| Q3 2020 | $3,725,000 | +4.6% | 15,039 | +11.5% | 0.17% | -0.6% |
| Q2 2020 | $3,560,000 | +42.5% | 13,483 | +2.3% | 0.17% | +19.7% |
| Q1 2020 | $2,499,000 | -13.6% | 13,184 | 0.0% | 0.14% | +10.9% |
| Q4 2019 | $2,894,000 | +37.5% | 13,184 | +22.5% | 0.13% | +33.3% |
| Q3 2019 | $2,105,000 | -8.6% | 10,759 | -2.6% | 0.10% | -8.6% |
| Q2 2019 | $2,304,000 | +5.0% | 11,051 | 0.0% | 0.10% | +2.9% |
| Q1 2019 | $2,194,000 | +35.7% | 11,051 | -1.1% | 0.10% | +15.9% |
| Q4 2018 | $1,617,000 | -29.1% | 11,172 | 0.0% | 0.09% | -16.2% |
| Q3 2018 | $2,280,000 | +37.9% | 11,172 | 0.0% | 0.10% | +32.9% |
| Q2 2018 | $1,653,000 | -2.0% | 11,172 | 0.0% | 0.08% | -2.5% |
| Q1 2018 | $1,687,000 | +16.6% | 11,172 | 0.0% | 0.08% | +22.7% |
| Q4 2017 | $1,447,000 | +4.7% | 11,172 | 0.0% | 0.07% | 0.0% |
| Q3 2017 | $1,382,000 | +5.3% | 11,172 | 0.0% | 0.07% | +3.1% |
| Q2 2017 | $1,313,000 | +17.4% | 11,172 | +1.6% | 0.06% | +16.4% |
| Q1 2017 | $1,118,000 | -4.3% | 10,999 | -3.1% | 0.06% | -6.8% |
| Q4 2016 | $1,168,000 | -6.0% | 11,355 | 0.0% | 0.06% | -13.2% |
| Q3 2016 | $1,243,000 | +87.2% | 11,355 | +93.0% | 0.07% | +58.1% |
| Q2 2016 | $664,000 | +25.8% | 5,884 | +5.4% | 0.04% | +22.9% |
| Q1 2016 | $528,000 | +5.2% | 5,582 | 0.0% | 0.04% | +2.9% |
| Q4 2015 | $502,000 | -2.7% | 5,582 | 0.0% | 0.03% | -8.1% |
| Q3 2015 | $516,000 | -6.2% | 5,582 | 0.0% | 0.04% | +2.8% |
| Q2 2015 | $550,000 | -1.8% | 5,582 | 0.0% | 0.04% | -2.7% |
| Q1 2015 | $560,000 | +10.7% | 5,582 | +1.9% | 0.04% | +5.7% |
| Q4 2014 | $506,000 | – | 5,476 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |